A policy recommendation will be issued when sufficient data are available on the properties of variant-updated vaccines compared to those based on the ancestral strain. This statement is not a policy recommendation. This statement reflects the current understanding of variants of concern (VOC) and variant-updated vaccines and highlights the gaps in evidence and potential implications for vaccination strategies. The World Health Organization (WHO) with support of Strategic Advisory Group of Experts (SAGE) on Immunization and its COVID-19 Vaccines Working Group, continues to review the emerging evidence on variant-updated vaccines.
#HAVE BEEN UPDATED OR HAS BEEN UPDATED FULL#
The full public health benefit of variant-updated vaccines and their value proposition over current vaccines can only be quantified once vaccine effectiveness data have been obtained.Policy recommendations will address different use-case scenarios for Omicron-updated vaccines and include consideration of programmatic aspects. Once these vaccines have received WHO emergency use authorization or approval by a stringent national regulatory authority, they will be considered by SAGE for policy recommendations. Variant-updated vaccines are under clinical development and will in due course be assessed by regulatory authorities.Such vaccines should aim to provide even greater and more durable protection against severe disease and death, and broader protection against future variants that may be even more antigenically distant to the index virus.
There is therefore a need to assess whether variant-updated COVID-19 vaccines, especially to Omicron, would improve vaccine performance. However, the emergence of variants of concerns has resulted in a rapid decline of the protection against symptomatic illness.
#HAVE BEEN UPDATED OR HAS BEEN UPDATED SERIES#
Achieving high coverage rates with the primary series and first booster doses in the highest and high priority-use groups in every country remains the priority.
0 kommentar(er)
